Early observations and pilot data that first suggested a new direction
Open wound management relied on wet-to-dry dressings and passive drainage for centuries until Argenta and Morykwas published their seminal 1997 paper describing vacuum-assisted closure (VAC) in animal models and clinical cases. They demonstrated that subatmospheric pressure at -125 mmHg applied through a foam dressing increased granulation tissue formation by 63%, improved local blood flow, and reduced bacterial counts. This mechanobiological approach to wound healing represented a fundamental paradigm shift, offering an alternative to repeated surgical debridement and prolonged open wound care. The technique was rapidly adopted for complex wounds including diabetic ulcers, open fractures, and dehisced surgical wounds.
Landmark RCTs and pivotal trials that established the evidence base
The first significant RCT evidence came from Blume et al. in 2008, a multicenter trial randomizing 342 patients with diabetic foot ulcers to NPWT versus standard moist wound therapy. NPWT achieved significantly higher complete wound closure rates (43% vs 29%) and more granulation tissue formation. In orthopedic trauma, the WOLLF trial randomized patients with severe open fractures to NPWT versus standard dressings and found reduced deep infection rates. A Cochrane systematic review in 2014 examined the evidence across wound types and found moderate-quality evidence supporting NPWT for diabetic foot ulcers and open fractures, though evidence for many other indications remained low quality.
Follow-up studies, subgroup analyses, and real-world validation
The application of NPWT expanded to closed surgical incisions (ciNPWT), representing a new paradigm of prophylactic use rather than treatment of established wounds. The PICO trial and multiple RCTs demonstrated that ciNPWT reduced surgical site infections in high-risk incisions (cesarean sections, abdominal surgery, orthopedic procedures). Portable, single-use NPWT devices (PICO, Prevena) made outpatient therapy feasible. Instillation NPWT (NPWTi-d), which intermittently delivers antiseptic or saline solution to the wound bed before applying suction, showed promise for infected wounds. However, Cochrane reviews consistently noted that much of the evidence was industry-sponsored with moderate risk of bias.
Integration into clinical practice guidelines and recommendations
Multiple specialty guidelines now incorporate NPWT. The International Wound Bed Preparation Advisory Board recommends NPWT for complex open wounds that are not progressing with standard care. The ABA includes NPWT in burn wound management protocols. NICE has conducted technology appraisals noting cost-effectiveness concerns for routine use but supporting NPWT for specific indications including open fractures and diabetic foot ulcers. Consensus statements from WUWHS (World Union of Wound Healing Societies) provide practical guidance on pressure settings, dressing changes, and duration of therapy.
WUWHS Consensus Document on NPWT
NPWT recommended for acute and chronic wounds not progressing with standard care, including diabetic foot ulcers, open fractures, dehisced surgical wounds, and partial-thickness burns. Standard pressure -125 mmHg; continuous mode for most wounds.
NICE Medical Technologies Guidance: PICO Negative Pressure Wound Therapy
Single-use NPWT may be considered for closed surgical incisions at high risk of surgical site infection. Cost-effectiveness depends on baseline SSI risk; most beneficial when baseline risk >10%.
Now
Current standard of care and ongoing research directions
NPWT has become a ubiquitous tool in wound management, generating a multi-billion dollar device market. The evidence base is strongest for diabetic foot ulcers and open fractures, with growing support for closed-incision applications in high-risk surgical populations. Key ongoing debates include the cost-effectiveness of prophylactic ciNPWT (device cost vs SSI prevention savings), optimal pressure settings and mode (continuous vs intermittent), the role of instillation NPWT for infected wounds, and the relative paucity of high-quality industry-independent trials. Newer technologies including smart NPWT systems with real-time wound monitoring sensors and biodegradable wound fillers represent the next evolution of the technology.
What is the evidence that NPWT actually improves wound healing?+
The strongest RCT evidence supports NPWT for diabetic foot ulcers (43% vs 29% complete closure) and open fractures (reduced deep infection). For other wound types, evidence is mostly observational or from small RCTs. Cochrane reviews note moderate-quality evidence overall with significant industry sponsorship bias in available trials.
Should NPWT be used on closed surgical incisions?+
Closed-incision NPWT (ciNPWT) has shown benefit in reducing surgical site infections for high-risk incisions (obesity, diabetes, repeat surgery). However, routine use on low-risk incisions is not cost-effective. Guidelines recommend targeting patients with baseline SSI risk >10% where the device cost is offset by infection prevention savings.
What are the contraindications to NPWT?+
Absolute contraindications include exposed blood vessels, untreated osteomyelitis, necrotic tissue with eschar (requires debridement first), malignancy in the wound, and unexplored fistulas. Relative contraindications include anticoagulation therapy (increased bleeding risk) and difficult wound hemostasis. The foam should never be placed directly on exposed organs or anastomoses.
